Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy

Inclusion Criteria: * Men and women between 18 and 55 years old. * They should be in good general health, confirmed by a medical history and physical examination, with negative clinical evaluation for leprosy. * Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on study vaccination days (D0, D28, and D56). They must not be breastfeeding and must use at least one method of contraception from the time of study enrollment (Day 0) through 30 days after the last injection if they have sex with men. * Screening laboratory tests with normal, within laboratory reference limits for: sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine, glucose, total WBC count, hemoglobin and platelet count. Abnormal results may be repeated at the discretion of the Principal Investigator and/or sub-investigators, who may share doubts with the sponsor's Scientific Leader and if necessary, with the DSMB. * Negative serological tests for: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. * Normal or not clinically significant urinalysis as determined by the study doctor or designee. Abnormal results may be repeated at the discretion of the Principal Investigator. * Must be able to complete the study adverse events diary. * Must consent to participate in the study, be able and willing to make all evaluation visits, be accessible by telephone or home visit…